Appendix 4C - Quarterly
Summary
<p class="typography-body-regular">The latest 4C report from Emyria highlights our collaborations with leading organisations & the beginning of recruitment for our Phase 3 clinical trial of EMD-RX5 - which has already come to fruition with January's dosing announcement! </p>
Your question will be sent privately to Emyria. The company may choose to make this question public.
Start the conversation
Ask Emyria a question about this announcement.
Share your feedback
Discover